Alvotech (ALVO): Firm Reaffirms 2025 Growth Outlook [Yahoo! Finance]
Alvotech - Ordinary Shares (ALVO)
Company Research
Source: Yahoo! Finance
The firm recently launched a $100 million offering of senior unsecured convertible notes due 2030 and reaffirmed its 2025 outlook while providing initial guidance for 2026. In 2026, Alvotech anticipates total revenues in the range of $650-$700 million, reflecting continued sales growth. Adjusted EBITDA is expected to increase to $180-$220 million, supported by higher volumes of commercialized products and launches of newly approved products in Europe and Japan. On November 12, Alvotech (NASDAQ:ALVO) posted third-quarter results, posting earnings per share of $0.47, beating estimates by $0.49. Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year. Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last year, per the firm. Alvotech (NASDAQ:ALVO) develops and manufactures biosimilar medicines for patients worldwide. While we acknowledge the potential of AL
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Alvotech announces European launch of biosimilar to Simponi [Seeking Alpha]Seeking Alpha
- Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma [Yahoo! Finance]Yahoo! Finance
- Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz PharmaGlobeNewswire
- Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVOPR Newswire
- Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® [Yahoo! Finance]Yahoo! Finance
ALVO
Earnings
- 11/12/25 - Beat
ALVO
Sec Filings
- 12/19/25 - Form 6-K
- 12/17/25 - Form 6-K
- 11/24/25 - Form 6-K
- ALVO's page on the SEC website